Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Danaher Corp., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).


The analysis of the financial ratios over the observed periods reveals notable trends and shifts in operational efficiency and asset utilization.

Net Fixed Asset Turnover

The net fixed asset turnover ratio shows a declining trajectory over the timeframe. Starting at 6.83 in the first recorded quarter, the ratio increased moderately to a peak of 8.40 before experiencing a sustained decrease. By the most recent quarter, the ratio had diminished to 4.52. This pattern suggests a reduction in the ability to generate revenue per unit of fixed assets, indicating potentially less efficient use of fixed assets over time or increased investment in fixed assets not yet translated into proportional revenue gains.

Total Asset Turnover

Total asset turnover exhibits an initial upward movement, rising from 0.29 to a high of 0.39, followed by a gradual decline that dips back near the original levels around 0.29 to 0.31. This indicates that the overall efficiency of the company in utilizing its total assets to generate sales improved temporarily but faced some deterioration towards the end of the period. The fluctuations imply varying returns on total asset investments, possibly influenced by operational changes or asset base growth.

Equity Turnover

The equity turnover ratio follows a pattern of increase and subsequent decline. Beginning at 0.56, the ratio climbed to 0.67, reflecting enhanced utilization of shareholders' equity to drive sales. After hitting this peak, the ratio steadily decreased, falling to 0.46 by the final quarter. This reversal signifies a reduced efficiency in converting equity into revenue, which may reflect changes in equity structure, profitability dynamics, or company strategy adjustments affecting equity deployment.

In summary, the company experienced early improvements in asset and equity utilization ratios, which peaked and then entered a period of decline. The steady reduction in net fixed asset turnover is especially pronounced, meriting further investigation into asset management practices or capital expenditure impacts. The total asset and equity turnovers also show declining tendencies post-peak, suggesting a broader trend of diminishing efficiency in asset and equity use to generate revenue. Continuous monitoring and potentially corrective operational or financial strategies may be advisable to address these efficiency declines.


Net Fixed Asset Turnover

Danaher Corp., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data (US$ in millions)
Sales
Property, plant and equipment, net of accumulated depreciation
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Net fixed asset turnover = (SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024 + SalesQ3 2024) ÷ Property, plant and equipment, net of accumulated depreciation
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The sales figures exhibit a general upward trajectory from April 2020 through December 2021, with a peak of 8,148 million US dollars in the last quarter of 2021. Following this peak, sales values demonstrate some volatility with notable decreases and recoveries, ultimately declining toward mid-2025 to approximately 5,936 million US dollars. This pattern indicates periods of growth followed by fluctuations, suggesting potential variability in market conditions or operational factors impacting revenue generation over time.

The net book value of property, plant, and equipment, net of accumulated depreciation, shows a consistent upward trend throughout the analyzed periods. Starting at 2,989 million US dollars in April 2020, this asset category steadily increases to reach 5,309 million US dollars by June 2025. This continuous growth suggests ongoing investments or capital expenditures in fixed assets, which could be related to capacity expansion, modernization, or maintenance of operational capabilities.

The net fixed asset turnover ratio, which measures sales generated per unit of net fixed assets, displays a declining trend from early 2021 onward. Initial values around 6.83 to 8.40 in 2020 and early 2021 decrease progressively to approximately 4.52 by June 2025. This decline in turnover indicates that the company is generating less sales per unit of fixed asset value over time, which may reflect reduced efficiency in asset utilization or changes in product mix and pricing strategies.

Summary of Key Trends:
- Sales increased substantially until late 2021, followed by volatility and a gradual decline through mid-2025.
- Property, plant, and equipment values consistently rose throughout the entire period, indicating sustained capital investment.
- Net fixed asset turnover ratio declined steadily from 2021 onwards, highlighting decreased efficiency in generating sales from fixed assets.
Insights:
The divergence between rapidly increasing fixed assets and declining asset turnover suggests the company might be experiencing challenges in translating capital investments into proportional sales growth. Operational strategies may require review to enhance asset productivity. Moreover, the observed sales volatility post-2021 could point to fluctuating demand or competitive pressures, warranting further detailed analysis into market dynamics and internal operational execution.

Total Asset Turnover

Danaher Corp., total asset turnover calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data (US$ in millions)
Sales
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Total asset turnover = (SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024 + SalesQ3 2024) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


Sales Trend
Sales demonstrated a general upward trend from April 2020 through December 2022, increasing from approximately 4,343 million USD to 8,369 million USD. After peaking in the fourth quarter of 2022, sales exhibited some volatility and a declining tendency over the subsequent quarters into mid-2025. Notably, sales fell sharply in the first quarter of 2023 to 5,949 million USD, remaining relatively subdued with fluctuations through mid-2025, ranging between approximately 5,700 and 6,500 million USD.
Total Assets Trend
Total assets showed a gradual increase during the initial periods, moving from around 68,930 million USD in early 2020 to a peak of approximately 87,734 million USD in the third quarter of 2023. Following this peak, total assets experienced a mild declining trend, dropping to roughly 79,116 million USD by mid-2025. Despite this recent decrease, asset levels remained elevated compared to the initial periods.
Total Asset Turnover Ratio Analysis
The total asset turnover ratio indicated incremental improvement between late 2020 and late 2022, rising from 0.29 to 0.39, implying enhanced efficiency in generating sales from assets. However, after reaching this peak, the ratio declined gradually, stabilizing around 0.28 to 0.31 from early 2023 through mid-2025, reflecting a reduction in asset utilization efficiency over recent periods.
Overall Insights
The data suggests that while the company achieved substantial growth in sales and asset base through 2022, more recent quarters showed a deceleration or contraction in sales alongside a slight reduction in total assets. Concurrently, asset turnover ratios reached optimal levels around 2022 before declining, which may point to challenges in maintaining asset utilization efficiency amid recent changing market or operational conditions. The fluctuation in sales, coupled with declining turnover ratios, could warrant further investigation into operational effectiveness and market dynamics affecting performance in the latest reporting periods.

Equity Turnover

Danaher Corp., equity turnover calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data (US$ in millions)
Sales
Total Danaher stockholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Equity turnover = (SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024 + SalesQ3 2024) ÷ Total Danaher stockholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The data reveals several noteworthy trends across the examined periods. Sales figures, expressed in millions of US dollars, demonstrate an overall upward trajectory from April 2020 through December 2021, increasing from 4,343 million to 8,148 million. This growth phase is followed by a period of volatility and decline, with sales decreasing sporadically and reaching a low of 5,624 million in September 2023. However, toward the end of the timeline, sales seem to recover somewhat, climbing again to 6,538 million by December 2024 before slightly tapering off in the first half of 2025.

Total Danaher stockholders’ equity, also presented in millions of US dollars, shows a positive and steady increase throughout the full period. Beginning at 31,055 million in April 2020, equity rises consistently to peak at 53,486 million in December 2023. Although there is a slight decrease in mid-2024, the equity remains relatively stable above 49,000 million through mid-2025, suggesting sustained shareholder value despite fluctuations in sales.

Equity turnover, measured as a ratio, appears from late 2020 onward. Initially, it increases gradually from 0.56 to 0.67 by the end of 2021, indicating improving efficiency in utilizing equity to generate sales during this period. After December 2021, the ratio declines steadily to about 0.44 by mid-2024, reflecting reduced turnover efficiency. The ratio shows a slight rebound near the end of the dataset, fluctuating around 0.46 to 0.48 through mid-2025, but it remains below its earlier peak levels.

Sales
Show a strong growth phase through 2021, followed by volatility and partial recovery toward the end of the period.
Total Stockholders’ Equity
Exhibits consistent growth, indicating stronger capital base and shareholder value despite sales fluctuations.
Equity Turnover
Increases initially, reflecting improved operational efficiency, then declines significantly, signaling decreased efficiency in converting equity to sales, with some minor recovery in the last periods.

Overall, the analysis suggests that while the company successfully expanded its equity base over time, sales performance experienced more variability and a recent decline in efficiency. The combination of rising equity and fluctuating sales illustrates differential dynamics between the company’s capital structure and operational revenue generation capacity during the reviewed quarters.